{"disease":{"id":"recurrent-nasopharynx-carcinoma","name":"recurrent nasopharynx carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT07332247","title":"PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":94,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT02538510","title":"Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT01847326","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT02339558","title":"Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01316757","title":"Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false},{"nct_id":"NCT00470496","title":"Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT02035527","title":"Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02706691","title":"BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of Chicago","has_results":true}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}